OS Therapies Stock Forum

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...

$OS Therapies (OSTX.US)$ up up up!
$Serve Robotics (SERV.US)$

$Serve Robotics (SERV.US)$ hope we get a good movement today $OS Therapies (OSTX.US)$

$OS Therapies (OSTX.US)$ 🚀🚀🚀

$OS Therapies (OSTX.US)$
Osteosarcoma is relatively rare, 1,000 cases per year, but more prevalent among children, making it more serious.
Other information:
2% of all childhood cancers
8th most common cancer in children
Most common bone malignancy

$OS Therapies (OSTX.US)$ to the moon🚀🚀🚀

$Serve Robotics (SERV.US)$ hoping for a good movement later. 👍 $OS Therapies (OSTX.US)$